{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:30Z","timestamp":1787841330592,"version":"build-2784847793"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,6]],"date-time":"2016-03-06T00:00:00Z","timestamp":1457222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Molecular monitoring of\n                      <jats:italic toggle=\"yes\">BCR\u2014ABL1<\/jats:italic>\n                      transcript levels using quantitative polymerase chain reaction is an essential part of the modern management of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Establishing the diagnostic\n                      <jats:italic toggle=\"yes\">BCR\u2014ABL1<\/jats:italic>\n                      fusion transcript is necessary in order to select appropriate primers and probes for such monitoring. A case is described in which quantitative polymerase chain reaction failed to detect the presence of\n                      <jats:italic toggle=\"yes\">BCR\u2014ABL1<\/jats:italic>\n                      fusion transcript in a Philadelphia chromosome-positive chronic myeloid leukemia patient. Further investigation demonstrated a novel in-frame\n                      <jats:italic toggle=\"yes\">BCR\u2014ABL1<\/jats:italic>\n                      fusion transcript with a breakpoint in\n                      <jats:italic toggle=\"yes\">BCR<\/jats:italic>\n                      exon 13 and insertion of a sequence of\n                      <jats:italic toggle=\"yes\">ABL1<\/jats:italic>\n                      intron 1, therefore enabling subsequent molecular monitoring. This case highlights the requirement for characterization of the\n                      <jats:italic toggle=\"yes\">BCR\u2014ABL1<\/jats:italic>\n                      transcript type at chronic myeloid leukemia diagnosis. Issues concerning standardized methodological approaches and interpretation of transcript levels in such rare cases are discussed.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2016.02.002","type":"journal-article","created":{"date-parts":[[2016,3,17]],"date-time":"2016-03-17T16:02:52Z","timestamp":1458230572000},"page":"85-88","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Characterization of a novel variant BCR\u2013ABL1 fusion transcript in a patient with chronic myeloid leukemia"],"prefix":"10.4103","volume":"10","author":[{"given":"Mireille","family":"Crampe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Haslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eibhlin","family":"Conneally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Langabeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.hemonc.2016.02.002_b0005","first-page":"186","article-title":"An optimized multiplex polymerase chain reaction (PCR) for detection of BCR\u2013ABL fusion mRNAs in hematological disorders","volume":"8","author":"Cross","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2016.02.002_b0010","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: investigation of minimal residual disease in acute leukemia","volume":"13","author":"van Dongen","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2016.02.002_b0015","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.leukres.2007.08.017","article-title":"A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts","volume":"32","author":"Burmeister","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.hemonc.2016.02.002_b0020","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2174\/156652412800619996","article-title":"BCR\/ABL1 fusion transcripts generated from alternative splicing: implications for future targeted therapies in Ph+ leukemias","volume":"12","author":"Chiarella","year":"2012","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.hemonc.2016.02.002_b0025","doi-asserted-by":"crossref","first-page":"8652","DOI":"10.1038\/sj.onc.1206194","article-title":"BCR\/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations","volume":"21","author":"Pane","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.hemonc.2016.02.002_b0030","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s12032-013-0508-9","article-title":"Is the BCR\u2013ABL1 transcript type in chronic myeloid leukaemia relevant?","volume":"30","author":"Langabeer","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.hemonc.2016.02.002_b0035","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2016.02.002_b0040","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.6004\/jnccn.2014.0159","article-title":"Chronic myelogenous leukemia, version 1.2015","volume":"12","author":"O\u2019Brien","year":"2014","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.hemonc.2016.02.002_b0045","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia \u2013 A Europe Against Cancer Program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2016.02.002_b0050","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/sj.leu.2400917","article-title":"A novel BCR\u2013ABL rearrangement in a Philadelphia chromosome-positive chronic myelogenous leukemia variant with thrombocythemia","volume":"12","author":"Rubinstein","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2016.02.002_b0055","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/sj.leu.2404174","article-title":"Rational use of the EAC real-time quantitative PCR protocol in chronic myelogenous leukemia: report of three false-negative cases at diagnosis","volume":"20","author":"Dessars","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2016.02.002_b0060","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1515\/CCLM.2009.202","article-title":"A novel aberrant form of e13a2 BCR\u2013ABL1 transcript in chronic myelogenous leukemia undetectable with the standardized real-time quantitative polymerase chain reaction from the Europe Against Cancer Program","volume":"47","author":"Matsushita","year":"2009","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.hemonc.2016.02.002_b0065","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3109\/10428190903572219","article-title":"Failure of molecular diagnostics in chronic myeloid leukemia: an aberrant form of e13a2 BCR-ABL transcript causing false-negative results by standard polymerase chain reaction","volume":"51","author":"Jurcek","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hemonc.2016.02.002_b0070","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1751-553X.2011.01346.x","article-title":"A novel, variant BCR\u2013ABL1 transcript not detected by standard real-time quantitative PCR in a patient with chronic myeloid leukemia","volume":"134","author":"McCarron","year":"2012","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.hemonc.2016.02.002_b0075","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/gcc.22263","article-title":"Molecular characterization and follow-up of five CML patients with new BCR\u2013ABL1 fusion transcripts","volume":"54","author":"Huet","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.hemonc.2016.02.002_b0080","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.humpath.2014.04.017","article-title":"Novel BCR\u2013ABL1 fusion identified by targeted next-generation sequencing in a patient with an atypical myeloproliferative neoplasm","volume":"45","author":"Frederick","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.hemonc.2016.02.002_b0085","first-page":"458052","article-title":"Optimal molecular methods in detecting p190 (BCR\u2013ABL) fusion variants in hematologic malignancies: a case report and review of the literature","volume":"2015","author":"Sonu","year":"2015","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.hemonc.2016.02.002_b0090","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2016.02.002_b0095","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2016.02.002_b0100","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2016.02.002_b0105","first-page":"232","article-title":"Deep molecular response in chronic myeloid leukemia: the new goal of therapy?","volume":"30","author":"Mahon","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hemonc.2016.02.002_b0110","doi-asserted-by":"crossref","first-page":"969","DOI":"10.5858\/arpa.2014-0522-LE","article-title":"Standardized molecular monitoring for variant BCR-ABL1 transcripts in chronic myeloid leukemia","volume":"139","author":"Langabeer","year":"2015","journal-title":"Arch Pathol Lab Med"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387616300024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387616300024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201710020-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:50:04Z","timestamp":1787838604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201710020-00006"}},"subtitle":["Implications for molecular monitoring"],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2016.02.002","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}